氢化可的松减量至100 mg/天可降低脓毒性休克患者高血糖发生率
这项双盲随机对照试验纳入80例脓毒性休克且液体和血管活性药治疗后仍血流动力学不稳定的患者,均分两组分别接受氢化可的松100 mg/天或200 mg/天静脉治疗,逐步减量并于第8天停药。主要观察指标高血糖发生率在100 mg组显著低于200 mg组(63.9% vs 86.5%,校正HR 0.08,95%CI 0.02-0.41,P=0.002)。100 mg组休克逆转时间更短(2天 vs 4天,P=0.031)。校正SAPS II后28天死亡率无显著差异(HR 0.68,95%CI 0.37-1.24,P=0.209),两组再感染率和消化道出血率相当。
要点
- 脓毒性休克患者氢化可的松100 mg/天组高血糖发生率63.9%,显著低于200 mg/天组的86.5%(校正HR 0.08,95%CI 0.02-0.41,P=0.002)。
- 100 mg/天组休克逆转时间2天,短于200 mg/天组的4天(P=0.031)。
- 校正SAPS II后28天死亡率两组无显著差异(HR 0.68,95%CI 0.37-1.24,P=0.209)。
- 两组再感染率和消化道出血率相当。
- 研究采用双盲随机对照设计,80例脓毒性休克伴血流动力学不稳定患者,氢化可的松逐步减量并于第8天停药。
适用人群与场景
- 脓毒性休克患者,尽管接受液体和血管活性药物治疗仍存在血流动力学不稳定。
处置流程与药物剂量
- 氢化可的松100 mg/天或200 mg/天静脉给药,逐步减量并于第8天停药(原文未写明具体减量方案和给药频次)。
研究设计与关键结果
- 双盲随机对照试验,纳入80例脓毒性休克患者,均分两组接受氢化可的松100 mg/天或200 mg/天静脉治疗。
- 高血糖发生率:100 mg组63.9% vs 200 mg组86.5%(校正HR 0.08,95%CI 0.02-0.41,P=0.002)。
- 休克逆转时间:100 mg组2天 vs 200 mg组4天(P=0.031)。
- 校正SAPS II后28天死亡率:HR 0.68(95%CI 0.37-1.24,P=0.209),无显著差异。
- 再感染率和消化道出血率两组相当。
证据类型、等级与局限
- 证据类型:双盲随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于脓毒性休克患者,作者认为与目前指南推荐的200 mg/天相比,氢化可的松100 mg/天可降低高血糖发生率且不增加死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The current international guideline recommended 200 mg/day of hydrocortisone intravenously to treat septic shock. However, a subsequent study on cortisol metabolism actually showed an increase in cortisol level during sepsis. Hence, the smaller hydrocortisone dose of 100 mg/day might be sufficient and reduce steroid-associated complications. We aimed to compare the clinical outcomes of minimized hydrocortisone dose of 100 mg to the currently recommended dose in the treatment of septic shock patients.
METHODS: A double-blinded randomized controlled trial included 80 septic shock patients with hemodynamic instability despite fluid and vasopressive therapy. Participants were divided equally into two groups to treat with 100 mg/day or 200 mg/day of hydrocortisone, then stepwise down titrated and discontinued on day 8. The outcome of interest was the hyperglycemic rate. Vital status, time to shock reversal, superinfection and gastrointestinal bleeding rates were also compared.
RESULTS: Patients with 100 mg hydrocortisone had significantly lower hyperglycemic rate compared with 200 mg, 63.9% versus 86.5% (the adjusted hazard ratio [HR], 0.08; 95% confidence interval [CI], 0.02-0.41, P = 0.002). Time to shock reversal was shorter in patients with 100 mg hydrocortisone, 2 days vs. 4 days, P = 0.031. The 28-day mortality rate when adjusted for Simplified Acute Physiology Score II showed no significant difference (HR, 0.68; 95% CI, 0.37-1.24, P = 0.209). The reinfection and gastrointestinal bleeding rates were comparable between groups.
CONCLUSION: Minimized daily hydrocortisone dosage of 100 mg could lower the occurrence of hyperglycemia without increasing mortality in septic shock, compared with the currently recommended dosage of 200 mg/day.
参考来源
- Ngaosuwan K, Ounchokdee K, Chalermchai T, et al. Clinical Outcomes of Minimized Hydrocortisone Dosage of 100 Mg/Day on Lower Occurrence of Hyperglycemia in Septic Shock Patients. Shock. 2018. PMID: 29176402. doi:10.1097/SHK.0000000000001061
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。